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ABSTRACT 
 A simple, precise, accurate and reliable HPTLC method has been developed and validated for analysis of Clidinium Bromide (CLBr), Pantoprazole Sodium 
(PNT) and Chlordiazepoxide (CDZ) in their combined dosage form. Identification and analysis were performed on 100mm x 100mm layer thickness 0.2 mm, 
pre-coated silica gel 60F254 aluminum sheet, prewashed with methanol and dried in an oven at 50°C for 5 min. Chloroform: Acetone: 0.5M Ammonium acetate 
in Methanol: Formic acid (1.0:5.0:3.0:1.0) (v/v/v/v) was used as mobile phase. Calibration plots were established showing the dependence of response (peak 
area) on the amount chromatographed. The validated calibration ranges were 600-1600 ng/spot, 4800-12800ng/spot and 1200-3200 ng/spot for CLBr, PNT 
and CDZ with correlation coefficient (R 
2) 0.998, 0.994 and 0.998 respectively. Average % recovery was between 99.63 – 99.89%, 99.87 – 100.05% and 
99.77-99.93% for CLBr, PNT and CDZ respectively. The spots were scanned at 220nm in a reflectance mode. The proposed method has been validated as per 
ICH guidelines and successfully applied to the estimation of CLBr, PNT and CDZ in their combined Capsule dosage form. 
Key Words: Clidinium Bromide, Chlordiazepoxide, Pantoprazole Sodium, HPTLC, Validation. 
 
INTRODUCTION 
Ulrax Capsule contains CLBr, CDZ and PNT in combination. 
It is useful to treat Irritable bowel syndrome which is a brain 
gut  disorder  characterized  most  commonly  by  cramping, 
abdominal pain, bloating, constipation, and diarrhea, which is 
the most common and fatal disease.
1 CLBr is chemically 3-
[(2-hydroxy-2,2-diphenylacetyl)oxy]-1-methyl-1  azabicyclo 
[2.2.2]  octan-1-ium  bromide  (Figure  1a),  which  inhibits 
muscarinic  actions  of  acetylcholine  at  postganglionic 
parasympathetic  neuroeffector  sites.  It  is  used  for  the 
treatment  of  peptic  ulcer  disease  and  also  to  help  relieve 
abdominal  or  stomach  spasms  or  cramps  due  to  colicky 
abdominal pain, diverticulitis, and irritable bowel syndrome.
6 
CLBr  is  official  in  United  state  pharmacopoeia  XXX
6. 
Chemically  PNT  is,  (RS)-5(Difluoromethoxy)  -
2[(3,4dimethoxypyridin  -2  yl)methyl  sulfinyl]-1H-benzo 
[d]imidazole sodium (Figure 1b), a benzimidazole derivative 
blocks  the  proton  pump  by  reacting  with  (H+/k+)-ATPase 
enzyme  by  causing  it’s  inhibition  of  action  resulting  long 
lasting  inhibition  of  gastric  acid  secretion.
2.  and  CDZ  is 
chemically  7-Chloro-N-methyl-5-phenyl-3H-1,4-
benzodiazepin-2-amine  4-oxide  (Figure  1c),  which  is  an 
anxiolytic  &    agonist  at  specific  benzodiazepine  receptor,  
which  are  inhibitory  in  nervous  system,  Chlordiazepoxide 
and  GABA  forms  complex  with  chloride  ion  leads  to 
stimulation  of  benzodiazepine  receptors  and  potentiate  the 
action of GABA which in turn controls the flow of chloride 
ions  across  neuron  membrane,  thereby  relieves  the  patient 
from  anxiety.  PNT  and  CDZ  are  official  in
,  British 
Pharmacopoeia
5, United States Pharmacopoeia
7   and  Indian 
Pharmacopoeia.
3,4 
The  review  of  literature  revealed  that  various  analytical 
methods involving spectrophotometry, HPLC, HPTLC have 
been reported for CLBr, PNT and CDZ in single form and in 
combination with other drugs while few analytical methods 
have been reported for CLBr and CDZ in combination with 
each other including HPLC, and HPTLC.
8-55 
To  the  best  of  our  knowledge,  there  is  no  published 
chromatographic  method  for  these  three  combinations  of 
drugs. So, the present paper describes a simple, accurate and 
precise  method  for  simultaneous  estimation  of  CLBr,  PNT 
and  CDZ  in  combined  capsule  dosage  form  by  HPTLC 
method. The developed method was validated in accordance 
with  ICH  Guidelines
56  and  successfully  employed  for  the 
assay  of  CLBr,  PNT  and  CDZ  in  their  combined  dosage 
form.  
 
MATERIALS AND METHODS 
Reagents and Chemicals 
Analytically  pure CLBr and PNT were kindly provided by 
Mission  Research  Laboratories  (I)  Pvt.  Ltd.,  Chandigarh-
160019,  India  and  Vasudha  Pharma  Chem  Limited, 
Hyderabad,  AP,  India  respectively  as  gratis  samples  while 
CDZ  was  provided  by  Aum  Research  Laboratories, 
Ahmedabad,  Gujarat,  India.  Analytical  grade  chloroform, 
methanol,  ammonium  acetate  and  formic  acid  were 
purchased from SD Fines chemicals, Bombay, India. Capsule 
of CLBr, PNT and CDZ in combined dosage form, ULRAX, 
with a 2.5 mg CLBr, 5mg CDZ and 20 mg PNT label claim, 
manufactured by Mission Research Laboratories (I) Pvt. Ltd., 
Chandigarh, India was procured from local market.  
 
Instrumentation and conditions 
Chromatography was performed on 100mm x 100mm on pre-
coated silica gel 60F254 aluminum sheet (E. Merck, Mumbai, 
India). Before use the plates were washed with methanol then 
dried  at  room  temperature.  Samples  were  applied  as  6mm 
bands  by  means  of  a  Camag  Linomat  V  (Muttenz, 
Switzerland) sample applicator equipped with 100µL syringe; 
operated  with  settings  of  band  length,  6  mm;  distance 
between bands, 5 mm; distance from the plate edge, 10 mm; 
and  distance  from  the  bottom  of  the  plate,  10  mm..  The 
constant  application    rate  was  15  s  μL–1  and  a  nitrogen 
aspirator  was  used.  Ascending  development  of  plate, 
migration  distance  70mm  was  performed  at  ambient 
temperature  with  Chloroform:  Acetone:  0.5M  Ammonium Dharati Rami et al. Int. Res. J. Pharm. 2013, 4 (4) 
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acetate in Methanol: Formic acid (1.0:5.0:3.0:1.0) (v/v/v/v), 
as  mobile  phase  in  a  10  cm  ×  10  cm  Camag  twin-trough 
chamber previously saturated for 15 min. After development 
the  plates  were  dried  with  hot-hair  dryer  and  viewed  in  a 
CAMAG UV cabinet. Densitometric scanning at 220nm was 
then performed with a Camag TLC Scanner 3 equipped with 
WinCATs 3.2.1 software. The scanning rate was 20 mm s
-1. 
The source of radiation used was the deuterium lamp. 
 
Calibration 
Clidinium  bromide  (200  μg/ml),  Chlordiazepoxide  (400 
μg/ml), and Pantoprazole sodium (1600 μg/ml) standard 
stock solution 
Standard CLBr 12.5 mg, CDZ 25mg and PNT 100 mg were 
weighed  and  transferred  to  a  25  ml  volumetric  flask  and 
dissolved in methanol. The flask was shaken and volume was 
made  up  to  the  mark  with  methanol  to  give  a  solution 
containing  500  μg/ml  CLBr,  1000  μg/ml  CDZ  and  4000 
μg/ml  PNT.  10  ml  of  this  aliquot  was  added  to  25  ml 
volumetric flask and Volume was made up to the mark with 
methanol to give a solution containing 200 μg/ml CLBr, 400 
μg/ml CDZ and 1600 μg/ml PNT. 
 
Calibration curve for CLBR, CDZ and PNT 
Semi automatic spotter was used containing a syringe having 
capacity  of  100  μl.  Mixed  stock  solution  having 
concentration  of 200  μg/ml  of CLBr, 400 μg/ml CDZ  and 
1600μg/ml PNT was filled in the syringe and under nitrogen 
stream, it was apply in form of band of desired concentration 
range for each of drug on a single plate having concentration 
of 600 to 1600 ng/spot for CLBr, 1200 to 3200 ng/spot for 
CDZ  & 4800 to 12800 ng/spot for PNT. Plate was developed 
using  above  mentioned  conditions.  Plots  of  peak  area  vs. 
concentration for three drugs were obtained. 
 
Analysis of marketed formulation 
Commercially  marketed  formulations  of  ULRAX  were 
purchased.  Twenty  capsules  were  weighed  carefully, 
equivalent amount of solid content was weighed accurately. 
A quantity equivalent to 12.5 mg CLBr, 25 mg CDZ and 100 
mg  was  accurately  weighed  and  transferred  to  volumetric 
flask of 25 ml capacity. 15 ml of methanol was transferred to 
this volumetric flask and sonicated for 20 min to dissolve the 
drug. Resulting solution was filtered through whattman filter 
paper (0.45μ) in to a 25ml volumetric flask. The flask was 
shaken and volume was made up to the mark with methanol 
to give a solution containing  500 μg/ml of CLBr, 1000 μg/ml 
of CDZ & 4000 μg/ml of PNT. 10  ml  of this aliquot was 
added to 25 ml volumetric flask and volume was made up to 
the  mark  with  methanol  to  give  a  solution  containing  200 
μg/ml of CLBr, 400 μg/ml of CDZ & 1600 μg/ml of PNT. 5 
µl of this aliquot was applied on TLC plate, developed, dried 
in air and photometricaly analyzed as described above which 
containing  1000  ng/spot  of  CLBr,  2000ng/spot  CDZ  and 
8000  ng/spot  of  PNT.  From  the  peak  area  obtained  in  the 
densitogram, the amounts of three drugs were calculated. 
 
Validation of the method 
Linearity and range of the HPTLC method 
Calibration graphs were constructed by plotting peak areas vs 
concentrations of CLBr, CDZ and PNT, and the regression 
equations  were  calculated.  The  calibration  graphs  were 
plotted  over  6  different  concentrations  in  the  range  of 
600‐1600 ng/spot for CLBr, 1200-3200ng/spot for CDZ and 
4800-12800 ng/spot for PNT by applying different volumes 
stock solution containing CLBr, CDZ and PNT (200 μg/ml of 
CLBr,  400  μg/ml  of  CDZ  and  1600  μg/ml  of  PNT).The 
calibration graphs were developed by plotting peak area vs 
concentrations  (n  =  6)  with  the  help  of  the  winCATS 
software. 
 
Accuracy (Recovery) 
Known  amounts  of  standard  solution  of  CLBr  (600,1200, 
1800  ng/spot),  CDZ  (1200,2400,  3600  ng/spot)    and  PNT 
(4800,  9600,  12800  ng/spot)  for  the  HPTLC  method  were 
added to prequantitated sample solutions of capsule dosage 
forms. The amounts of CLBr, CDZ and PNT were estimated 
by applying values of peak area to the regression equations of 
the calibration graph. 
 
Precision 
Precisions of the proposed HPTLC methods were determined 
by analyzing mixed standard solution of TOL and DFS at 3 
different concentrations (800,1000, 1200 ng/spot for CLBr, 
1600,2000,  2400  ng/spot  for  CDZ    and  6400,8000,9600 
ng/spot for PNT) 3 times on the same day and on 3 different 
days.  The  results  are  reported  in  terms  of  coefficient  of 
variance (CV). 
 
Repeatability 
Repeatability of method was assessed by applying the same 
sample solution 6 times on a plate with the automatic spotter 
using the same syringe and by taking 6 scans of the sample 
spot for triple drugs CLBr, CDZ and PNT (1000 ng/spot of 
CLBr,  2000ng/spot  of  CDZ  and  8000  ng/spot  of  PNT) 
without changing the positions of the plate.  
 
Specificity  
The specificity of the method was ascertained by analyzing 
standard drug and sample. The band of CLBr, CDZ and PNT 
in sample was confirmed by comparing the Rf and spectra of 
the band with that of standard. The peak purity of three drugs 
were assessed by comparing the spectra at 3 different level, 
i.e. peak start (S), peak apex (M) and peak end (E) position of 
the band. 
 
Limit of Detection & Limit of Quantification 
The limit of detection (LOD) and the limit of quantification 
(LOQ)  of  the  drug  were  derived  by  using  the  following 
equations as per International Conference on Harmonization 
(ICH) guidelines which is based on the calibration curve.  
LOD = 3.3 × σ /S 
LOQ = 10 × σ /S 
Where σ = the standard deviation of y-intercepts of 
regression lines, S = Slope of calibration curve. 
 
Robustness 
Sample solution was prepared and then analyzed with change 
in  the  typical  analytical  conditions  like  amount  of  mobile 
phase,  proportion  of  mobile  phase,  saturation  time,  plate 
pretreatment and Stability of analytical solution.  
 
RESULTS  
Method Optimization 
Several  mobile  phases  were  tried  to  accomplish  good 
separation of CLBr, CDZ and PNT. Using the mobile phase 
Chloroform: Acetone: 0.5M Ammonium acetate in Methanol: 
Formic acid (1.0:5.0:3.0:1.0) (v/v/v/v) and 10×10 cm HPTLC 
silica gel 60 F254 aluminum‐backed plates, good separation 
was  attained  with  retention  factor  (Rf)  values  of  0.54  for Dharati Rami et al. Int. Res. J. Pharm. 2013, 4 (4) 
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CLBr, 0.66 for PNT and 0.76 for CDZ. A wavelength of 220 
nm was used  for the quantification  of the drugs. Figure. 2 
shows the detection of  three drugs  in their combined dosage 
form at 220nm by HPTLC method. Resolution of the peaks 
with clear baseline separation was found. Figure. 3 shows the 
densitogram of mixture which has a clear baseline. Figure. 4 
showed  a  good  linearity  when  overlapped  and  scanned 
between 200nm to 400nm. Figure. 5 shows a 3D overlapped 
spectrum  of  both  the  drugs  which  has  good  linearity.  The 
system suitability test parameters for the developed method 
are shown in Table 1. 
 
Table 1: System Suitability Test Parameters 
 
System suitability Parameter  CLBr  PNT  CDZ 
Peak Purity  0.9999  0.9998  0.9993 
Rf value  0.54  0.66  0.76 
 
Table 2: Result of calibration readings for CLBr by HPTLC method 
 
Concentration (ng/spot)  Area Mean  ±  S.D. (n=6)  C.V. 
600  1003.38 ±2.2515  0.22 
800  1564.68 ± 3.2027  0.20 
1000  2133.70 ± 5.1571  0.24 
1200  2678.48 ± 11.1965  0.41 
1400  3138.50 ± 7.0279  0.22 
1600  3786.03 ± 4.3292  0.11 
 
Result of calibration readings for PNT by HPTLC method 
 
Concentration (ng/spot)  Area Mean  ±  S.D. (n=6)  C.V. 
4800  2971.66 ±7.5425  0.25 
6400  4132.60± 6.4149  0.15 
8000  6254.66±5.4825  0.087 
9600  8190.41± 5.7422  0.070 
11200  10472.95± 10.1699  0.097 
12800  12136.5± 7.8467  0.064 
 
 
Result of calibration readings for CDZ by HPTLC method 
 
Concentration (µg/spot)  Area Mean  ±  S.D. (n=6)  C.V. 
1200  1157.91±6.9127  0.59 
1600  2086.1±5.7720  0.27 
2000  2861.26±8.4582  0.29 
2400  3715.08±9.8692  0.26 
2800  4530.9±7.1484  0.15 
3200  5591±6.0246  0.10 
 
Table 3: Determination of Accuracy 
 
% 
Level 
Amount Added 
(ng/spot) 
Mean of Amount Recovered 
(ng/spot) (n=3) 
% Mean Recovery ± S.D 
(n=3) 
CLBr  PNT  CDZ  CLBr  PNT  CDZ  CLBr  PNT  CDZ 
50  600  4800  1200  597.8  1797.8  1197.367  99.63± 
0.3064 
99.87± 
0.2030 
99.77± 
0.2705 
100  1200  9600  2400  1196.4  4802.8  2397.267  99.70 ± 
0.3538 
100.05± 
0.1011 
99.88 
± 0.1934 
150  1800  12800  3600  1798.2  9598.2  3597.767  99.89± 
0.2289 
99.97± 
0.0602 
99.93± 
0.1588 
 
Table 4: Summary of validation Parameters of HPTLC 
 
Parameters  CLBr  PNT  CDZ 
Recovery %  99.63 – 99.89  99.87 – 100.05  99.77-99.93 
Repeatability (C.V., n=6)  0.60  0.11  0.29 
Precision (C.V.) 
Intra - day (n=3) 
Inter - day (n=3) 
 
0.17 – 0.18 
0.12 – 0.31 
 
0.025 – 0.107 
0.012 – 0.074 
 
0.019-0.039 
0.039-0.043 
Limit of Detection (μg/ml)  4.6725  30.81165  12.61327 
Limit of Quantitation (μg/ml)  14.1583  93.36863  38.22203 
Specificity  Specific  Specific  Specific 
Robustness  Robust  Robust  Robust 
Solvent suitability  Suitable for 24hr  Suitable for 24hrs  Suitable for 24hr 
 
Table 5: Assay result of marketed formulation 
 
Formulation  Drug 
 
Amount Taken 
(ng/spot) 
Amount Found 
(ng/spot) (n = 3) 
Labeled 
Claim (mg) 
Amount found per 
Capsule (mg) 
% Label 
claim ±SD 
 
Ulrax 
(capsule) 
CLBr  1000  1000.72  2.5  2.59  101.63 ± 0.8946 
CDZ  2000  2000.58  5  5.19  100.19 ± 0.5431 
PNT  8000  8000.61  20  20.25  100.29 ± 0.4441 
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(a)       (b)        (c) 
 
Figure 1: Chemical structure of (a) CLBr, (b) PNT and (c) CDZ 
 
 
 
Figure 2: Photograph of developed HPTLC plate of CLBr, PNT and CDZ 
at 220nm 
 
 
 
Figure 3: Densitogram of standard solution of market formulation 
containing CLBr, PNT and CDZ 1000 ng/spot, 8000 ng/spot,and 2000 
ng/spot, respectively 
 
 
 
Figure 4: Overlain spectrum of 600-1600ng/spot  CLBr, 4800-12800 
ng/spot PNT, and 1200-3200 ng/spot CDZ  at 220 nm 
 
 
 
Figure 5: 3D overlain spectra of CLBr, PNT, and CDZ by HPTLC 
method 
 
Linearity 
Linear  correlation  was  obtained  between  peak  areas  and 
concentrations  of  CLBr  in  the  range  of  600-1600  ng/spot 
with  R
2=0.998,  1200-3200ng/spot  for  CDZ  with  R
2=0.998 
and 4800-12800 ng/spot for PNT with R
2=0.994, respectively 
and data are shown in table 2. 
 
Accuracy 
The  recovery  experiments  were  performed  by  the  standard 
addition  method.  The  HPTLC  method  was  found  to  be 
accurate with % recovery of 99.63 – 99.89% for CLBr, 99.87 
– 100.05% for PNT and 99.77-99.93% for CDZ  respectively 
(Table  3).  The  high  values  indicate  that  the  method  is 
accurate. 
 
Repeatability 
The CV values for CLBr, CDZ and PNT were found to be 
0.60,0.29 and 0.11 respectively. The CV values were found 
to  be  <1%,  which  indicates  that  the  proposed  methods  is 
repeatable. 
 
Precision 
The CV values were found to be <2%, which indicates that 
the proposed method is precise. 
 
Limit  of  Detection  (LOD)  and  Limit  of  Quantification 
(LOQ) 
LOD  values  for  CLBr,  CDZ  and  PNT  were  found  to  be 
4.6725  ng/spot,  12.61327ng/spot    and  30.81165  ng/spot 
respectively.  LOQ  values  for  CLBr,  CDZ  and  PNT  were 
found  to  be  14.1583  ng/spot,  38.22203ng/spot  and 
93.36863ng/spot  respectively.  These  data  shows  that 
nanogram  quantity  of  three  drugs  can  be  accurately 
determined. (Table 4) 
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Specificity 
Excipients  used  in  the  specificity  studies  did  not  interfere 
with the estimation  of either  of the drugs by the  proposed 
methods. Hence, the methods were found to be specific for 
estimation of CLBr, CDZ and PNT. 
 
Robustness 
Peak area  and retention factor   variation were  found to  be 
<1%. Also, no significant change in peak area was observed 
during 24 Hrs. No decomposition was observed in either the 
first  or  second  direction  of  the  2‐dimensional  analysis  for 
both  drugs  on  the  HPTLC  plate.  Hence,  the  method  was 
found to be robust for estimation of CLBr, CDZ and PNT. 
 
Assay  of  the  capsule  dosage  form  (CLBR  2.5mg,  CDZ 
5mg and PNT 20 mg per capsule) 
The proposed validated method was successfully applied to 
determine CLBr, CDZ and PNT in their capsule dosage form 
(ULRAX).  The  results  obtained  for  CLBr,  CDZ  and  PNT  
was  comparable  with  the  corresponding  labelled  amounts 
(Table 5). 
 
DISCUSSION 
Thus,  the  objective  of  project  work  was  development  and 
comparison of analytical method of CLBr , CDZ and PNT  in 
their  combined  dosage  form.  The  developed  and  validated 
HPTLC method for CLBr, CDZ and PNT was found to be 
simple specific and cost effective and can be routine applied 
for  analysis  of  CLBr,  CDZ  and  PNT  in  their  combined 
dosage  form.  We  can  say  that  HPTLC  method  is  more 
sensitive giving precise results (interday, intraday) for three 
drugs & also HPTLC method is more sensitive in terms of 
LOD and LOQ.  It also requires least solvents for analysis. 
The proposed method has the advantages of simplicity and 
convenience  for  the  separation  and  quantitation  of  CLBr, 
CDZ and PNT in combination and can be used for the assay 
of their dosage form. Also, the low solvent consumption and 
short  analytical  run  time  lead  to  environmentally  friendly 
chromatographic procedures. The additives usually present in 
the pharmaceutical formulations of the assayed analytes did 
not interfere with determination of CLBr, CDZ and PNT. The 
method can be used for the routine simultaneous analysis of 
CLBr, CDZ and PNT in pharmaceutical preparations. 
 
ACKNOWLEDGEMENT 
Authors  are  thankful  to  Mission  Research  Laboratories  (I)  Pvt.  Ltd. 
(Chandigarh, India), Vasudha Pharma Chem Limited (Hyderabad, India) and 
Aum Research Labs.(Ahmadabad,  India) for providing gratis  sample  with 
the great pleasure. The authors also thankful to Indubhai Patel College of 
Pharmacy and Research Centre (Dharmaj, India) for providing the necessary 
facilities for research work and to all the staff members and friends for their 
guidance and help throughout the research work. 
 
REFERENCES 
1.  Rami  Dharati,  Shah  Nehal,  Patel  Pinak,  Rami  Vivek,  “Review  on 
Various Approaches to Treat Irritable Bowel Syndrome and Superiority 
of Combinations over the Existing Therapy.” Inventi Impact: Molecular 
Pharmacology, 2013, (1). 
2.  The  Merck  index,  an  encyclopaedia  of  chemicals,  drugs  &biological, 
14
th Edition, pp. 7014,2084, 2354 
3.  Indian Pharmacopoeia, Govt. Of  India “Ministry of  Health & Family 
Welfare” The Controller & Publication, Delhi (Vol-III) 2010, pp. 1856-
1858. 
4.  Indian Pharmacopoeia, Govt. Of  India “Ministry of  Health & Family 
Welfare” The Controller & Publication, Delhi (Vol-II) 2010, pp. 1054-
1056. 
5.  British Pharmacopoeia 2011, “The Stationery  Office on behalf of the 
Medicines  and  Healthcare  products  Regulatory  Agency  (MHRA)”, 
London, pp.1521, 319-320,203-204. 
6.  United  States  Pharmacopoeia  and  National  Formulary,  (30
th)  Asian 
Edition, The United   States Pharmacopoeia Convention  Inc., U.S.A., 
pp.1712-1716, 1777. 
7.  United  States  Pharmacopoeia  and  National  Formulary,  (32
th)  Asian 
Edition, The United States Pharmacopoeia Convention Inc., U.S.A., 24 
Pantoprazole/official  monograph,  14,  16Chlordiazepoxide  /  official 
monograph. 
8.  Suslu I., Altinoz S. and Yildiz E., “Determination of a Pantoprazole in 
Tablet Dosage Forms by Two Different Spectrophotometric Methods.” 
FABAD J Pharm Sci., 2003 28(2):85-92.  
9.   Kumar  R,  Singh  H  and  Singh  P.,  “Development  of  UV 
Spectrophotometric  method  for  estimation  of  Pantoprazole  in 
pharmaceutical dosage forms.” J Chem Pharm Res., 2011, 3(2):113-7.  
10.  Pandya  Jigar  ,Solanki  Sagar,  Patel  Mandev,  “Development  and 
Validation of Differential Spectrophotometric method for Determination 
of  Pantoprazole  in  Tablet  Dosage  Form.”  Journal  of  Pharmaceutical 
Science and Bioscientific Research, 2012, 2(1):2-4.  
11.   Niroush KonariSarif and Vipin Prakash, “Development and Validation 
of  RP-HPLC  and  Spectrophotometric  Method  for  simultaneous 
Estimation of Domperidone and Pantoprazole in Pharmaceutical Dosage 
Forms.” International Journal of Chemical and Analytical Science, 2011, 
2(8):133-135.  
12.  Kakde R.B., Gedam S.N., Chaudhary N.K., Barsagade A.G., Kale D.L. 
and Kasture  A.V., “Three wavelength Spectrophotometric Method for 
Simultaneous  Estimation  of  Pantoprazole  and  Domperidone  in 
Pharmaceutical  Preparations.”  International  Journal  of  PharmTech 
Research, 2009, 1(2):386-389.  
13.  Sloka  S.N.,  Gurupadayya  B.M.  Kumar  Ch.A.,  “Simultaneous 
Spectrophotometric  Determination  of  Naproxen  and  Pantoprazole  in 
Pharmaceutical Dosage Form.”Journal of Applied Chemical Research, 
2011, 17:65-74.  
14.  PanchalVihang U, ChauhanPrakash S., “Development and Validation of 
Dual  Wavelength  and  First  Order  Derivative  Spectrophotometric 
Methods  for  Simultaneous  Estimation  of  Ondansetron  Hydrochloride 
and  Pantoprazole  Sodium  in  their  Bulk  Dosage  Form.”Inventi  Rapid: 
Pharm Analysis & Quality Assurance, 2012(4): 1-7.  
15.  Savaliya PR, Bangoriya UV, Kakadia AK, “Development and validation 
of  Spectrophotometric  method  for  simultaneous  estimation  of 
Pantoprazole  sodium  and  Ondansetron  hydrochloride  in  combined 
dosage form.” Inventi rapid: Pharm analysis & quality assurance, 2012.  
16.  Patel Nishitkumar , Acharya  SP, Patel DA , Shah  AH , Baria DA, “ 
Validation  And  Application  Of  Spectrophotometric  And  HPTLC-
Densitometry  For  The  Simultaneous  Determination  Of  Ondansetron 
And  Pantoprazole  In  Pharmaceutical  Dosage  Form.”  Inventi  rapid: 
Pharm analysis & quality assurance, 2010.  
17.  Patel  SR,  Patel  NK,  Patel  DB,  Patel  PA,  Dr.  Patel  LJ,  “Derivative 
Spectrophotometric  Method  for  Simultaneous  Determination  of 
Granisetron  and  Pantoprazole  in  Synthetic  Mixture.”  International 
Journal for Pharmaceutical Research Scholars, 2012, 1(2):26.  
18.  Birajdar A, Meyyanathan S and Suresh B., “Determination of Mosapride 
and  Pantoprazole  in  A  fixed-dose  combination  by  UV 
Spectrophotometric  methods  and  RP-HPLC.”International  Journal  of 
Pharmaceutical Studies and Research,2011, 2(2):29-36.  
19.   Rama Chandraiah M and Rami Reddy Y, “Method Development and 
Validation  of  HPLC  for  the  Determination  and  Quantification  of 
Pantoprazole.”  Research  Journal  of  Pharmaceutical,  Biological  and 
Chemical Sciences, 2012, 3(3): 875.  
20.  SuddhasattyaDey  et  al,  “RP-HPLC  method  for  the  estimation  of 
Pantoprazole sodium in bulk and in dosage forms.” International Journal 
of Chemical and Analytical Science, 2011, 2(5): 34-36.  
21.  RaoKaretiSrinivasa,  KesharNargesh  Kumar,  ChoudhuryandPrasenjit 
Roy,  Pattnaik  Ajay  Kumar  “RP-HPLC  Method  for  the  Estimation  of 
Pantoprazole  Sodium.”  International  Journal  of  Pharma  Medicine  & 
Biological Science, 2012, 1(1): 48-53.  
22.  Reddy Prasanna, ReddyKiran Kumar, “Development and Validation of 
RP-HPLC for the Pantoprazole Sodium Sesquihydrate in Pharmaceutical 
dosage forms and Human Plasma.” International Journal of ChemTech 
Research, 2009, 1(2):195-198.  
23.  Krishna  G,  Rajesh  C  and  Sudhir  W,  “Stability  indicating  RP-HPLC 
method  for  simultaneous  determination  of  Pantoprazole  Sodium  and 
Itopride  Hydrochloride  in  bulk  and  capsule.”  Orbital  the  Electronic 
Journal of Chemistry, 2010, 2(3):3-9.  
24.  KumarRajnish,  SinghPinderjit,  SinghHarinder,  “Development  & 
Validation  of  RP-HPLC  method  for  simultaneous  estimation  of 
Naproxen & Pantoprazole in pharmaceutical dosage form.” International 
Journal of Pharmaceutical Research and Development, 2011, 2(12):227-
232.  
25.  Mohideen S. , Shivakanth M. , SureshKumar P. , Navaneetha Krishnan 
S.,Surendranath  Y.  and  Satyanarayana  T.,  “Development  And 
Validation  Of  Analytical  Method  For  Naproxen  And  Pantoprazole  In Dharati Rami et al. Int. Res. J. Pharm. 2013, 4 (4) 
Page 166 
Capsule Dosage Form.” Pelagia Research Library Der Pharmacia Sinica, 
2011, 2(6): 114-121.  
26.  Tated  A,  Khan  F,  Gadewar  C,  Bakal  R,  Dewani  A,  Chandewar  A, 
“Method  Development  And  Validation  For  The  Simultaneous 
Determination  Of  Naproxen  And  Pantoprazole  Sodium  In  Capsule 
Dosage Form By RP- HPLC.” International Journal of Pharmaceutical 
Research and Development, 2011, 3(5): 8-14.  
27.  Patel G.H, Prajapati S. T., Patel C. N., “Development and Validation of 
HPLC  Method  for  Simultaneous  Estimation  of  Cinitapride  and 
Pantoprazole in Pharmaceutical Dosage Form.” International Journal of 
Pharmacy and Techlonology, 2012, 4(2):4253-4260.  
28.  P.V. Hemalatha, A. Jerad Suresh and Niraimathi V, “RP-HPLC Method 
Development  and  Validation  for  the  Estimation  of  Cinitapride  and 
Pantoprazole in Solid Oral Dosage Form.” Asian Journal of Research in 
Chemistry, 2012, 5(2):221-224.  
29.  V  Ravichandiran,  V  M  Sumithra,  PullamRajuKolluri,  “Analytical 
Method Development and Validation for Simultaneous Determination of 
Cinitapride  and  Pantoprazole  by  RP-HPLC.”Inventi  Rapid:  Pharm 
Analysis &Quality Assurance, 2012, 2012(3):1-7.  
30.  Sivakumar  T,  Manavalan  R  and  Valliappan  K,  “Development  and 
Validation  of  a  Reversed-phase  HPLC  method  for  simultaneous 
determination  of  Domperidone  and  Pantoprazole  in  pharmaceutical 
dosage forms.” ACTA Chromatographica, 2007, 18:30-32.  
31.  SarifNiroush Konari and Vipin Prakash, “Development and Validation 
of  RP-HPLC  and  Spectrophotometric  Method  for  Simultaneous 
Estimation of Domperidone and Pantoprazole in Pharmaceutical Dosage 
Forms.” International Journal of Chemical and Analytical Science, 2011, 
2(8): 133-135.  
32.  Prasanna R, Mathsa J and  Kotta S, G. Jyothesh, Surendranath  R and 
B.Ravindra  Reddy,  “Determination  Of  Pantoprazole  Sodium  And 
Lansoprazole In Individual Dosage Form Tablets By RP-HPLC Using 
Single  Mobile  Phase.”  International  Journal  of  Applied  Biology  and 
Pharmaceutical Technology, 2010, 1(2): 683-888.  
33.  D.  VijayaBharathi  ,  Kishore  Kumar  Hotha,  B.  Jagadeesh,Pankaj  K. 
Chatki,  A  K.  Thriveni,  Ramesh  Mullangic  and  A.  Naidub, 
“Simultaneous  Estimation  Of  Four  Proton  Pump  Inhibitors 
Lansoprazole,  Omeprazole,  Pantoprazole  And  Rabeprazole: 
Development  of  A  Novel  Generic  HPLC-UV  Method  And  Its 
Application To Clinical Pharmacokinetic Study.”  
34.   Maryam Noubarani, Fariborz Keyhanfar, Manijeh Motevalian, Masoud 
Mahmoudian,  “Improved  HPLC  Method  for  Determination  of  Four 
PPIs,  Omeprazole,  Pantoprazole,  Lansoprazole  and  Rabeprazole  in 
Human  Plasma.”  Journal  of  Pharmacy  &  Pharmaceutical.  Sciences, 
2010, 13(1): 1-10.  
35.  BageshwarDeepak  ,KhanvilkarnVineeta,  KadamVilasrao,  “Stability 
Indicating High Performance Thin-Layer Chromatographic Method For 
Simultaneous  Estimation  Of  Pantoprazole  Sodium  And  Itopride 
Hydrochloride In Combined Dosage Form.” Journal of Pharmaceutical 
Analysis, 2010, 1(4):275–283.  
36.   Patel Satish, “HPLC Method for Estimation of Pantoprazole Injection.” 
International Research Journal of Pharmacy, 2011, 2(8): 132-135.  
37.  Gosavi  Seema,  Shirkhedkar  Atul,  Jaiswal  Yogini  And  SuranaSanjay, 
“Quantitative  Planer  Chromatographic  Analysis  Of  Pantoprazole 
Sodium  Sesquihydrate And Domperidone  In Table.”Journal Of Planar 
Chromatography,  2006,19:302-306. 
http://dx.doi.org/10.1556/JPC.19.2006.4.8 
38.  Patel GH, Prajapati ST and Patel CN, “HPTLC Method Development 
and  Validation  for  Simultaneous  Determination  of  Cinitapride  and 
Pantoprazole in Capsule Dosage Form.” Research Journal of Pharmacy 
and Technology, 2011, 4(9):1428-1431.  
39.  Gupta Surya Prakash, Upmanyu Neeraj and Garg Gopal, “Development 
and Validation of Spectrophotometric, HPTLC and HPLC methods for 
the  determination  of  Imipramine  and  Chlordiazepoxide  in 
pharmaceutical  dosage  forms.”  Pelagia  Research  Library,  Der 
Pharmacia Sinica, 2012, 3(2):185-192.  
40.  M.Ines  Toral,  Pablo  Richter,  Nelson  Lara,  Pablo  Jaque,  Cesar  Soto, 
Marcela  Saavedra, “Simultaneous  Determination  Of  Chlordiazepoxide 
And Clidinium Bromide In Pharmaceutical Formulations By Derivative 
Spectrophotometry.”  International  Journal  of  Pharmaceutics,  1999, 
189(1):67-74. http://dx.doi.org/10.1016/S0378-5173(99)00238-0 
41.  Haggag RS, Shaalan RA, Belal TS, “Validated HPLC determination of 
the two fixed dose combinations Chlordiazepoxide Hydrochloride And 
Mebeverine Hydrochloride; Carvedilol And Hydrochlorothiazide in their 
tablets.” Journal of AOAC International 2010, 93(4):1192-200.  
42.  Riddick  JH  Jr,  “An  ultraviolet  and  visible  spectrophotometric  assay 
method  for  chlordiazepoxide.”  ClinBiochem.  ,  1973,  6(3):189-99. 
http://dx.doi.org/10.1016/S0009-9120(73)80026-8 
43.  Patel  SK,  Patel  NJ,  “Simultaneous  determination  of  imipramine 
hydrochloride and chlordiazepoxide in pharmaceutical preparations by 
spectrophotometric,  RP-HPLC,  and  HPTLC  methods.”  J  AOAC  Int., 
2010, 93(3):904-10.  
44.   Pathak Ashutosh, Rai Pallavi, and Rajput Sadhana, “Stability-Indicating 
HPLC Method for Simultaneous Determination of Clidinium Bromide 
and  Chlordiazepoxide  in  Combined  Dosage  Forms.”  Journal  of 
Chromatographic Science, 2010:48.  
45.  Patel  SK.  and  Patel  NJ.  “Simultaneous  RP-HPLC  Estimation  of 
Trifluoperazine Hydrochloride and Chlordiazepoxide in Tablet Dosage 
Forms.”  Indian  J  Pharm  Sci.,  2009,  71(5):  545–547.  http://dx.doi.org 
/10.4103/0250-474X.58192 
46.  El-Hefnawey  G.B  ,  El-Hallag  I.S,  Ghoneim  E.M,  Ghoneim  M.M, 
“Voltammetric  behavior  and  quantification  of  the  sedative-hypnotic 
drugchlordiazepoxide  in  bulk  form,  pharmaceutical  formulation  and 
human  serum at a  mercury electrode.” Journal of Pharmaceutical and 
Biomedical  Analysis,  27  January  2004,  34(1):75-86. 
http://dx.doi.org/10.1016/j.japna.2003.08.008 
47.  El-Sayed  G.,  Yasin  S.  and  El-Badawy.,  “Adsorptive  Voltammetric 
Determination of Chlordiazepoxide in Pure and Dosage Forms.” Journal 
of Chemical and Pharmaceutical Research, 2009, 1(1): 225-232.  
48.  Davidson  AG,  “Assay  of  Chlordiazepoxide  and  Demoxepam  in 
Chlordiazepoxide  Formulations  By  Difference  Spectrophotometry.”  J 
Pharm Sci. 1984, 73(1):55-8. http://dx.doi.org/10.1002/jps.2600730114 
49.  Khoshayand  MR,  Abdollahi  H,  Moeini  A,  Shamsaie  A,  Ghaffari  A, 
Abbasian  S.,  “Simultaneous  spectrophotometric  determination  of 
Chlordiazepoxide and Clidinium Bromide using Multivariate Calibration 
Techniques.”Drug  Test  Anal.,  2010,  2(9):430-5.  http://dx.doi.org/ 
10.1002/dta.162 
50.  Peat  M.A.,  Chem  C.,  and  Ladislavkopjak  B.A.,  “The  Screening  and 
Uantitation  of  Diazepam,  Flurazepam,  Chlordiazepoxide,  and  Their 
Metabolites  in  Blood  and  Plasma  by  Electron-  Capture  Gas 
Chromatography  and  High  Pressure  Liquid  Chromatography.”  J 
Forensic Sci, 1979, 24(1).  
51.  Song D, Zhang S, Kohlhof K., “Determination of Chlordiazepoxide in 
mouse  plasma  by  Gas  Chromatography-Negative-Ion  Chemical 
Ionization Mass  Spectrometry.” J Chromatogr  B Biomed  Appl. 1994, 
660(1):95-101. http://dx.doi.org/10.1016/0378-4347(94)00282-7 
52.  Dixon  W.  R.,  Earley  J.,  Postma  E.,  “Radioimmunoassay  of 
chlordiazepoxide in plasma.” Journal of Pharmaceutical Sciences, 1975, 
64[6]: 937–939. http://dx.doi.org/10.1002/jps.2600640607 
53.  Dubois  J.G.,  Atassi  G.,  Hanocq  M.,  “HPLC  Determination  of 
Chlordiazepoxide its Metabolites and Oxaziridines Generated after UV 
Irradiation.”  J  Chromatogr  A,  1994,  662:255  –  262.  http://dx.doi.org/ 
10.1016/0021-9673(94)80513-X 
54.  82.  Nickerson  B,  “The  determination  of  a  degradation  product  in 
Clidinium  Bromide  drug  substance  by  Capillary  Electrophoresis  with 
indirect  UV  detection.”  J  Pharm  Biomed  Anal. ,  1997, 15(7):965-71. 
http://dx.doi.org/10.1016/S0731-7085(96)01922-X 
55.  Amin  S.,  DessoukiA.  ,  Moustafa  M.  and  Ghoname  S., 
“Spectrophotometric  methods  for  Sertraline  Hydrochloride  and 
Clidinium  Bromide  determination  in  bulk  and  pharmaceutical 
preparations.”  Chemical  Papers,  2009,  63:716-722. 
http://dx.doi.org/10.2478/s11696-009-0069-8 
56.  ICH  Harmonized  Tripartite  Guidelines,  Validation  of  analytical 
procedures: Text and Methodology, Q2 (R1), Geneva, 2005. 
 
Cite this article as:       
Dharati Rami, Nehal J. Shahl. Application of HPTLC-Densitometric analysis 
for simultaneous determination of Clidinium bromide, Chlordiazepoxide and 
Pantoprazole  sodium  in  their  combined  capsule  dosage  form.  Int.  Res.  J. 
Pharm. 2013; 4(4):161-166 
 
 
 
 
Source of support: Nil, Conflict of interest: None Declared 
 
 
 